Advertisement
Advertisement
As global markets navigate the complexities of Middle East tensions and energy market volatility, Asian indices have shown mixed performance with Japan's markets experiencing declines while China's mainland indices remained relatively stable. In this environment, identifying undervalued stocks becomes crucial as investors seek opportunities that may offer potential value amid geopolitical uncertainties and fluctuating market conditions.
Top 10 Undervalued Stocks Based On Cash Flows In Asia
Name | Current Price | Fair Value (Est) | Discount (Est) |
Zhuhai CosMX Battery (SHSE:688772) | CN¥14.69 | CN¥29.31 | 49.9% |
Xi'an NovaStar Tech (SZSE:301589) | CN¥155.53 | CN¥307.31 | 49.4% |
Vista Group International (NZSE:VGL) | NZ$1.64 | NZ$3.23 | 49.3% |
JAC Recruitment (TSE:2124) | ¥852.00 | ¥1684.03 | 49.4% |
Horizon Robotics (SEHK:9660) | HK$6.63 | HK$13.10 | 49.4% |
Higold Group (SZSE:001221) | CN¥61.75 | CN¥122.33 | 49.5% |
DIGITAL HEARTS HOLDINGS (TSE:3676) | ¥855.00 | ¥1675.22 | 49% |
CURVES HOLDINGS (TSE:7085) | ¥769.00 | ¥1511.97 | 49.1% |
Chongqing Zaisheng Technology (SHSE:603601) | CN¥14.00 | CN¥27.29 | 48.7% |
Avic Aviation High-Technology (SHSE:600862) | CN¥20.84 | CN¥40.65 | 48.7% |
Underneath we present a selection of stocks filtered out by our screen.
Ocumension Therapeutics
Overview: Ocumension Therapeutics, with a market cap of HK$6.98 billion, operates as an ophthalmic pharmaceutical platform company in the People's Republic of China through its subsidiaries.
Operations: The company's revenue segment focuses on discovering, developing, and commercializing ophthalmic therapies, generating CN¥804.35 million.
Estimated Discount To Fair Value: 20.9%
Ocumension Therapeutics is trading at 20.9% below its estimated fair value, with shares priced at HK$8.56 compared to a future cash flow valuation of HK$10.82. The company reported CNY 804.35 million in sales for 2025, up from CNY 417.31 million the previous year, and reduced its net loss significantly to CNY 158.82 million from CNY 268.27 million in the prior period, demonstrating strong revenue growth potential and improving financial health despite current losses.
Sheng Siong Group
Overview: Sheng Siong Group Ltd is an investment holding company that operates a chain of supermarket retail stores in Singapore, with a market cap of SGD4.33 billion.
Operations: The company generates revenue of SGD1.57 billion from its supermarket operations selling consumer goods in Singapore.
Estimated Discount To Fair Value: 16.8%
Sheng Siong Group is trading at 16.8% below its estimated fair value of SGD 3.46, with a current price of SGD 2.88, suggesting potential undervaluation based on cash flows. The company reported increased sales of SGD 1.57 billion and net income of SGD 149.46 million for the year ended December 2025, reflecting solid financial performance despite an unstable dividend track record and moderate earnings growth forecast at 6.71% annually, which surpasses the Singapore market average growth rate.
Beiqi Foton MotorLtd
Overview: Beiqi Foton Motor Co., Ltd. is involved in the manufacture and sale of commercial vehicles globally, with a market cap of CN¥23.75 billion.
Operations: The company's revenue primarily derives from its global commercial vehicle manufacturing and sales operations.
Estimated Discount To Fair Value: 33%
Beiqi Foton Motor Ltd. is trading at 33% below its estimated fair value of CN¥4.48, reflecting significant undervaluation based on cash flows. The company forecasts robust earnings growth of 39.1% annually, surpassing the Chinese market average of 26.4%. Recent strategic alliances with COSCO SHIPPING enhance global supply chain capabilities, positioning Foton for expanded international presence despite low forecasted return on equity and one-off items affecting earnings quality.
Advertisement
Advertisement
Advertisement
